FXN Antibody - #DF6590

(1)   (1)  
Product: FXN Antibody
Catalog: DF6590
Description: Rabbit polyclonal antibody to FXN
Application: WB IHC
Reactivity: Human, Mouse, Rat
Prediction: Zebrafish, Bovine, Horse, Sheep, Rabbit, Dog, Chicken
Mol.Wt.: 23kDa; 23kD(Calculated).
Uniprot: Q16595
RRID: AB_2838552

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MS Report
HPLC Report
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Prediction:
Zebrafish(91%), Bovine(92%), Horse(100%), Sheep(92%), Rabbit(100%), Dog(100%), Chicken(92%)
Clonality:
Polyclonal
Specificity:
FXN Antibody detects endogenous levels of total FXN.
RRID:
AB_2838552
Cite Format: Affinity Biosciences Cat# DF6590, RRID:AB_2838552.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

CyaY; d-FXN; FA; FARR; Frataxin mature form; Frataxin(81-210); FRDA; FRDA_HUMAN; Friedreich ataxia protein; Fxn; i-FXN; m56-FXN; m78-FXN; m81-FXN; MGC57199; X25;

Immunogens

Immunogen:
Uniprot:

Q16595(FRDA_HUMAN) >>Visit HPA database.

Gene(ID):
FXN(2395)
Expression:
Q16595 FRDA_HUMAN:

Expressed in the heart, peripheral blood lymphocytes and dermal fibroblasts.

Description:
FXN, also named as FRDA, X25, m81-FXN, d-FXN, m78-FXN and i-FXN, belongs to the frataxin family. It promotes the biosynthesis of heme and assembly and repair of iron-sulfur clusters by delivering Fe2+ to proteins involved in these pathways. FXN may play a role in the protection against iron-catalyzed oxidative stress through its ability to catalyze the oxidation of Fe2+ to Fe3+; the oligomeric form but not the monomeric form has in vitro ferroxidase activity. FXN is cleaved to be 4 chains. The mature form of FXN is 14kd or 18kd.
Sequence:
MWTLGRRAVAGLLASPSPAQAQTLTRVPRPAELAPLCGRRGLRTDIDATCTPRRASSNQRGLNQIWNVKKQSVYLMNLRKSGTLGHPGSLDETTYERLAEETLDSLAEFFEDLADKPYTFEDYDVSFGSGVLTVKLGGDLGTYVINKQTPNKQIWLSSPSSGPKRYDWTGKNWVYSHDGVSLHELLAAELTKALKTKLDLSSLAYSGKDA

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Horse
100
Dog
100
Rabbit
100
Bovine
92
Sheep
92
Chicken
92
Zebrafish
91
Pig
0
Xenopus
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - Q16595 As Substrate

Site PTM Type Enzyme
S81 Phosphorylation
T94 Phosphorylation
Y118 Phosphorylation P12931 (SRC)
Y143 Phosphorylation
S160 Phosphorylation
S161 Phosphorylation
K197 Acetylation
K197 Ubiquitination
Y205 Phosphorylation

Research Backgrounds

Function:

Promotes the biosynthesis of heme and assembly and repair of iron-sulfur clusters by delivering Fe(2+) to proteins involved in these pathways. May play a role in the protection against iron-catalyzed oxidative stress through its ability to catalyze the oxidation of Fe(2+) to Fe(3+); the oligomeric form but not the monomeric form has in vitro ferroxidase activity. May be able to store large amounts of iron in the form of a ferrihydrite mineral by oligomerization; however, the physiological relevance is unsure as reports are conflicting and the function has only been shown using heterologous overexpression systems. Modulates the RNA-binding activity of ACO1.

PTMs:

Processed in two steps by mitochondrial processing peptidase (MPP). MPP first cleaves the precursor to intermediate form and subsequently converts the intermediate to yield frataxin mature form (frataxin(81-210)) which is the predominant form. The additional forms, frataxin(56-210) and frataxin(78-210), seem to be produced when the normal maturation process is impaired; their physiological relevance is unsure.

Subcellular Location:

Mitochondrion. Cytoplasm>Cytosol.
Note: PubMed:18725397 reports localization exclusively in mitochondria.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Expressed in the heart, peripheral blood lymphocytes and dermal fibroblasts.

Subunit Structure:

Monomer (probable predominant form). Oligomer. Monomers and polymeric aggregates of >1 MDa have been isolated from mitochondria. A small fraction of heterologous overexpressed recombinant frataxin forms high-molecular wight aggregates that incoroprate iron. Interacts with LYRM4. Interacts with ACO1. Interacts with ISCU isoform 1 and isoform 2. Interacts with FECH; one iron-bound FXN monomer seems to interact with a FECH homodimer. Interacts with SDHA and SDHB. Interacts with ACO2; the interaction is dependent on citrate (By similarity). Interacts with HSPA9.

Family&Domains:

Belongs to the frataxin family.

Research Fields

· Metabolism > Metabolism of cofactors and vitamins > Porphyrin and chlorophyll metabolism.

References

1). Protective Role of Dioscin against Doxorubicin-Induced Chronic Cardiotoxicity: Insights from Nrf2-GPX4 Axis-Mediated Cardiac Ferroptosis. Biomolecules, 2024 (PubMed: 38672439) [IF=5.5]

Application: WB    Species: Rat    Sample:

Figure 8 Dioscin suppresses cardiac ferroptosis by regulating the Nrf2/GPX4 signaling pathway in DOX-induced rats. (A) Representative Western blotting images of Nrf2, HO-1, and TfR1 in DOX-induced rat treated with or without dioscin. (B–D) Bar charts indicate the protein expression levels of Nrf2, HO-1, and TfR1 in cardiac tissues. Data are mean ± SD (n = 3). (E–K) Bar charts indicate the mRNA expression levels of Nrf2, HO-1, TfR1, DMT1, FTL, FTH1, and FPN in cardiac tissues. Data are mean ± SD (n = 6). (L) Representative Western blotting images of NOX4, ABCB8, and FXN in DOX-induced rat treated with or without dioscin. (M–O) Bar charts indicate the protein expression levels of NOX4, ABCB8, and FXN in cardiac tissues. Data are mean ± SD (n = 3). (P–R) Bar charts indicate the mRNA expression levels of NOX4, ABCB8, and FXN in cardiac tissues. Data are mean ± SD (n = 6). (S) Representative images of immunofluorescence analysis of Nrf2 and NOX4 expression were captured by fluorescence microscopy. (T,U) The bar chart indicates the Nrf2 and NOX4 intensity in cardiac tissue. Data are mean ± SD (n = 3). * p < 0.05, ** p < 0.01, *** p < 0.001 vs. DOX treatment group; # p < 0.05, ## p < 0.01, ### p < 0.001 vs. control group. (A,L) Original western blotting figures can be found in Figures S5 and S6.

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.